PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 118 filers reported holding PARATEK PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 1.85 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $35,306 | -13.8% | 13,900 | -36.5% | 0.00% | – |
| Q4 2022 | $40,953 | -61.4% | 21,900 | -47.0% | 0.00% | -100.0% |
| Q3 2022 | $106,000 | +241.9% | 41,300 | +156.5% | 0.00% | – |
| Q2 2022 | $31,000 | -93.8% | 16,100 | -90.5% | 0.00% | -100.0% |
| Q1 2022 | $504,000 | -38.9% | 169,800 | +99.8% | 0.01% | -86.5% |
| Q3 2018 | $825,000 | -5.0% | 85,000 | -0.1% | 0.04% | -21.3% |
| Q2 2018 | $868,000 | -11.0% | 85,100 | +13.5% | 0.05% | -35.6% |
| Q1 2018 | $975,000 | -46.9% | 75,000 | -26.9% | 0.07% | -51.3% |
| Q4 2017 | $1,836,000 | -41.0% | 102,574 | -17.2% | 0.15% | -47.2% |
| Q3 2017 | $3,110,000 | -11.0% | 123,888 | -14.6% | 0.28% | -21.1% |
| Q2 2017 | $3,495,000 | +159.5% | 145,000 | +107.2% | 0.36% | +166.7% |
| Q1 2017 | $1,347,000 | – | 69,983 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |